Cargando…

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression

RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roberto, Michela, Falcone, Rosa, Mazzuca, Federica, Archibugi, Livia, Castaldi, Nadia, Botticelli, Andrea, Osti, Mattia Falchetto, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728821/ https://www.ncbi.nlm.nih.gov/pubmed/29310420 http://dx.doi.org/10.1097/MD.0000000000009023

Ejemplares similares

Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers
por: Facondo, Giuseppe, et al.
Publicado: (2023)

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
por: Quirino, Michela, et al.
Publicado: (2017)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review
por: Falcone, Rosa, et al.
Publicado: (2018)

How technology can help in oncologic patient management during COVID-19 outbreak
por: Mercantini, Paolo, et al.
Publicado: (2020)

Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
por: Marrari, Andrea, et al.
Publicado: (2020)

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B: A retrospective observational study
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
por: Kuo, Hsing-Tao, et al.
Publicado: (2017)

Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas
por: Fetcko, Kaleigh, et al.
Publicado: (2017)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis
por: Que, Jenny, et al.
Publicado: (2020)

Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy
por: Que, Jenny, et al.
Publicado: (2020)

Simultaneous treatment of two lung cancer lesions with stereotactic MR-guided adaptive radiation therapy: A case report
por: Chen, Frank, et al.
Publicado: (2023)

SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review
por: Payne, Heather A., et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity: A 5-year Follow-Up of an Investigational Study
por: Lee, Sea-Won, et al.
Publicado: (2014)

Re-irradiation of multiple brain metastases using CyberKnife stereotactic radiotherapy: Case report
por: Zhou, Han, et al.
Publicado: (2021)

Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma
por: Ji, Ren, et al.
Publicado: (2022)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas
por: Minniti, Giuseppe, et al.
Publicado: (2011)

Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis
por: Minniti, Giuseppe, et al.
Publicado: (2011)

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?
por: Nguyen, Nam P., et al.
Publicado: (2016)

Stereotactic body radiation therapy for the treatment of lymph node metastases: a retrospective mono-institutional study in a large cohort of patients
por: Caivano, Donatella, et al.
Publicado: (2023)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly
por: Wang, Peng, et al.
Publicado: (2016)

Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report
por: Yan, Hongxia, et al.
Publicado: (2020)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors
por: Franceschini, Davide, et al.
Publicado: (2023)

The usefulness of stereotactic radiosurgery for recursive partitioning analysis class II/III lung cancer patients with brain metastases in the modern treatment era
por: Ha, In Bong, et al.
Publicado: (2019)

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer
por: Li, Can, et al.
Publicado: (2020)

Evaluation of the prognostic value of derived neutrophil/lymphocyte ratio in early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy
por: Wang, Xin, et al.
Publicado: (2020)

A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report
por: Li, Juming, et al.
Publicado: (2020)

Radiation therapy for older patients with brain tumors
por: Minniti, Giuseppe, et al.
Publicado: (2017)

Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report
por: Maltoni, Roberta, et al.
Publicado: (2020)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

Linear accelerator-based stereotactic body radiation therapy in the treatment of oligometastatic disease
por: Yamashita, Hideomi, et al.
Publicado: (2020)

Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer
por: Hou, Xiaorong, et al.
Publicado: (2019)

The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
por: Roberto, Michela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a90nmesh0lctsgehmcks107595